Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

PURPOSE: In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) advanced breast canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Rugo, H. S., Finn, R. S., Diéras, V., Ettl, J., Lipatov, O., Joy, A. A., Harbeck, N., Castrellon, A., Iyer, S., Lu, D. R., Mori, A., Gauthier, E. R., Bartlett, C. Huang, Gelmon, K. A., Slamon, D. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438948/
https://www.ncbi.nlm.nih.gov/pubmed/30632023
http://dx.doi.org/10.1007/s10549-018-05125-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438948/
https://www.ncbi.nlm.nih.gov/pubmed/30632023
http://dx.doi.org/10.1007/s10549-018-05125-4

Ejemplares similares